Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a conditional payment tied to the timely FDA approval of atrasentan without a ...

Novartis' Vanrafia reduced proteinuria by 36.1% in IgAN patients using a RAS inhibitor. Continued FDA approval depends on Phase 3 ALIGN study results in 2026. Feel unsure about the market’s next ...

Joint research activities will be carried out at Novartis’ sites in Basel, Switzerland, and Dublin, Ireland, as well as at the Microsoft Research Lab in Cambridge, UK.

Speaking to journalists at Novartis headquarters in Basel, Switzerland, last week, Hughes said its recent in-licensing of a second NASH pipeline drug from Conatus would help put it in pole position.

Both are given twice a year. The clearance will likely help it better compete with Kesimpta by Novartis (NOVN.S), opens new tab, which patients can administer themselves through monthly injections.

Explore Novartis stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for NVS. Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...